At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 185 enrolled
Drug / intervention
botulinum toxin Type Abiological
Likely dose
botulinum toxin Type A 20 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines
In Brief
A Phase 4 clinical trial evaluating botulinum toxin Type A for Glabellar Rhytides. Completed, enrolled 185 participants across 1 site.
Detailed Summary
A study to evaluate safety and efficacy of treatment with botulinum toxin Type A (BOTOX®) in Chinese patients with moderate to severe frown lines (Glabellar Rhytides) previously treated with facial laser resurfacing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Rhytides
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
First PostedMar 2013
Primary CompletionJul 2014
Study CompletionOct 2014
TodayJul 2026
First PostedMar 20, 2013
Enrollment StartMar 6, 2013
Primary CompletionJul 31, 2014
Study CompletionOct 29, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 13.3 years ago
Interventions
botulinum toxin Type Abiological
20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.